Efeitos adversos do sufentanil associado ao anestésico local pelas vias subaracnóidea e peridural em pacientes submetidas à analgesia de parto

Salem, Isabel C F; Fukushima, Fernanda Bono; Nakamura, Giane; Ferrari, Fábio; Navarro, Laís C.; Castiglia, Yara Marcondes Machado; Ganem, Eliana Marisa

doi:10.1590/s0034-70942007000200001

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the inhibitory effects on cardiovascular and respiratory systems, sufentanil-induced gastrointestinal adverse effects, skin pruritus, and urinary retention are frequently observed side effects [30,37,38]. Salem et al reported that some women with epidural sufentanil analgesia during labor suffered severe nausea and pruritus drug administration [39]. We observed that women in group B1 experienced fewer side effects (nausea and urinary retention) following drug administration when compared with women in groups A and B2, with statistically significant differences.…”

Section: Discussionmentioning

confidence: 99%

Cytochrome P4503A4 gene polymorphisms guide safe sufentanil analgesic doses in pregnant Chinese mothers: a multicenter, randomized, prospective study

Shu,

Yan,

et al. 2023

Pharmacogenetics and Genomics

View full text Add to dashboard Cite

Background Sufentanil and ropivacaine when used as epidural anesthetics effectively reduce maternal pain during labor. From previous reports, rs2242480 single nucleotide polymorphisms (SNPs) can alter sufentanil metabolism, which affects analgesic efficacy. Methods We randomly divided 573 eligible mothers into groups A and B (in a 1 : 3 ratio). The control group (group A) was given sufentanil at the usual 0.5 mg/L-1 dose + 0.15% ropivacaine hydrochloride mixture in 10 ml. The sufentanil dose given to the intervention group (group B) was determined by genotype: the GA and AA genotype group (group B1) was given 87.6% (design based on previous study results) of the usual sufentanil clinical dose (0.438 mg/L-1 sufentanil + 0.15% ropivacaine hydrochloride mixture in 10 ml) and the GG genotype group (group B2) was given the same dose as group A. Efficacy indicators consisting of maternal vital signs, obstetric transfer, neonatal prognostic indicators, and adverse effects were recorded before and after analgesia across groups. Results Visual analog scale scores after analgesia across groups were significantly different from scores before analgesia, showing that analgesic effects across groups were effective. No significant differences were observed in efficacy, obstetric transfer, and neonatal prognosis indicators between groups. In comparison to groups B1 and B2, group A showed more markedly suppressed cardiovascular and respiratory effects, and also a higher incidence of negative side effects such as vomiting and urinary retention. Conclusion We confirmed that individualizing sufentanil doses based on maternal genotypes increased safety and success rates for women during childbirth.

show abstract